205 results on '"Rambaldi, A."'
Search Results
2. Second versus first wave of COVID-19 in patients with MPN
3. COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study
4. Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19
5. High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib
6. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus
7. Safety and efficacy of the maximum tolerated dose of givinostat in polycythemia vera: a two-part Phase Ib/II study
8. Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial
9. A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis
10. IDH1-R132 changes vary according to NPM1 and other mutations status in AML
11. Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts
12. Correction: Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19
13. A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis
14. Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System
15. PML-RARA-associated cooperating mutations belong to a transcriptional network that is deregulated in myeloid leukemias
16. Driver mutations’ effect in secondary myelofibrosis: an international multicenter study based on 781 patients
17. COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study
18. Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide
19. 18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease
20. Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group
21. Cell-based strategies to manage leukemia relapse: efficacy and feasibility of immunotherapy approaches
22. Second versus first wave of COVID-19 in patients with MPN
23. Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma
24. Comparison of outcomes after single or double cord blood transplantation in adults with acute leukemia using different types of myeloablative conditioning regimen, a retrospective study on behalf of Eurocord and the Acute Leukemia Working Party of EBMT
25. The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview
26. CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis
27. Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib
28. p38αMAPK interacts with and inhibits RARα: suppression of the kinase enhances the therapeutic activity of retinoids in acute myeloid leukemia cells
29. Mesenchymal stromal cells for the treatment of graft-versus-host disease: understanding the in vivo biological effect through patient immune monitoring
30. Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria
31. Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect
32. Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18–20 September 2008
33. The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2V617F
34. Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome
35. Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden
36. The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells
37. Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation
38. Development of a quantitative-PCR method for specific FLT3/ITD monitoring in acute myeloid leukemia
39. Elevated C-reactive protein is associated with shortened leukemia-free survival in patients with myelofibrosis
40. Gene expression profile unravels significant differences between childhood and adult Ph+ acute lymphoblastic leukemia
41. The CIBMTR score predicts survival of AML patients undergoing allogeneic transplantation with active disease after a myeloablative or reduced intensity conditioning: a retrospective analysis of the Gruppo Italiano Trapianto Di Midollo Osseo
42. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study
43. Purified autologous grafting in childhood acute lymphoblastic leukemia in second remission: evidence for long-term clinical and molecular remissions
44. Molecular profile of Epstein–Barr virus infection in HHV-8-positive primary effusion lymphoma
45. Outcome of patients activating an unrelated donor search: the impact of transplant with reduced intensity conditioning in a large cohort of consecutive high-risk patients
46. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease: Report of the BIOMED-1 Concerted Action: Investigation of minimal residual disease in acute leukemia
47. Primary effusion lymphoma after heart transplantation: a new entity associated with human herpesvirus-8
48. Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts
49. Reply to: Second primary malignancies in myeloproliferative neoplasms and the role of aspirin
50. The course of monoclonal 'villous' lymphocytosis over 15 years of follow-up: progression to SLVL or spontaneous clinical but not molecular remission
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.